Mode
Text Size
Log in / Sign up
N/A N=94 Diagnostic

Performance of an Investigational Blood Glucose Monitoring System in a Clinical Setting

Diabetes

Enrolled (actual)
94
Serious AEs
0.0%
Results posted
May 2012
Primary outcome: Primary: Numbers of Fingerstick Blood Glucose (BG) Results Within +/- 5 to 20mg/dL (<75 mg/dL) or Within +/- 5% to 20% (>=75 mg/dL) of Laboratory Glucose Method — 180; 179; 172; 138 Number of BG test results

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Ninja 2 Investigational Blood Glucose Monitoring System (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Ascensia Diabetes Care
Primary completion
Dec 2010

Outcome Measures

OutcomeResultp-value
PRIMARY
Numbers of Fingerstick Blood Glucose (BG) Results Within +/- 5 to 20mg/dL (<75 mg/dL) or Within +/- 5% to 20% (>=75 mg/dL) of Laboratory Glucose Method
180; 179; 172; 138
SECONDARY
Numbers of Palm Blood Glucose (BG) Results Within +/- 5 to 20 mg/dL (<75 mg/dL) or Within +/- 5% to 20% (>=75 mg/dL) of Laboratory Glucose Method
166; 161; 143; 82
SECONDARY
Number of Subjects Rated as<=3 Performing Basic Meter Tasks (Labeling Comprehension)
93; 93; 93; 93; 90; 90
SECONDARY
Numbers of Forearm Blood Glucose (BG) Results Within +/- 5 to 20 mg/dL (<75 mg/dL) or Within +/- 5% to 20% (>=75 mg/dL) of Laboratory Glucose Method
158; 145; 125; 74

Summary

The purpose of this study is to evaluate the performance and acceptability of an investigational blood glucose monitoring system, which includes meter and sensor strip.

Eligibility Criteria

Inclusion Criteria

  • Males and females, 18 years of age and above
  • Type 1 or type 2 diabetes
  • Currently self-testing blood glucose at home at least twice daily
  • Able to speak, read, and understand English
  • Willing to complete all study procedures

Exclusion Criteria

  • Currently Pregnant
  • Hemophilia or any other bleeding disorder
  • Employee of competitive medical device company
  • Cognitive disorder or other condition which, in the opinion of the investigator, would put the person at risk or seriously compromise the integrity of the study
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01268267). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search